NGM Bio
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
333 Oyster Point Blvd, South San Francis...Phone Number
(650) 243-5555Website
www.ngmbio.comRevenue
$28.3 MillionStock Symbol
NGMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About NGM Bio
We are a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move biologic drug candidates rapidly into proof-of-concept clinical studies.Explore more
NGM Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NGM Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NGM Bio launches new products
NGM Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NGM Bio
Website visits: Recent activity has been detected on your website
Click to see if NGM Bio had a recent Job posting/layoffs
Check out if NGM Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NGM Bio has new funding data
Earning: See what the market has to say on NGM Bio recently announced quarterly report
Check if NGM Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at NGM Bio
Find more new buyers
Compare Similar Companies to NGM Bio
Compare insights from companies similar to NGM Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NGM Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NGM Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NGM Bio.
NGM Bio financials insights
Gather financial insights about NGM Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series A
$25.5M
2010
Series B
$51M
2013
Series C
$50M
2015
Series D
$57.5M
2019
Stock Offering
$65.9M
2024
Series A
$122M
NGM Bio Tech Stack
A closer look at the technologies used by NGM Bio
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
NGM Bio News & Media
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
NGM Bio today announced the appointment of Wendy Yeh, M.D. as Chief Medical Officer.NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
NGM Bio and KdT Ventures today announced the signing of a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-klotho agonist drug candidate.3 months after taking NGM Bio private, VC firm oversees biotech's $122M series A
Three months after The Column Group acquired NGM to take the biotech private, the VC firm has overseen a series A to fund trials of two lead assetsNGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio), a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced a $122 million Series A financing led by TCG with participation from a select group of investors. NGM Bio will use the proceeds from the Series A financing to initiate a planned registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NGM Bio
Sign Up For FreeTo access detailed company insights
We are a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move biologic drug candidates rapi... Read More
